Stay informed with the latest litigation news. Explore now
Medicaments For Increasing Endogenous Erythropoietine (Epo) - EP2289531B1
EP2289531
- Application Number
- EP10181768A
- Filing Date
- Dec 6, 2002
- Status
- Granted And Under Opposition
- Jun 1, 2018
- Grant Date
- Jul 4, 2018
- External Links
- Slate, Register, Google Patents
- Similar Patents facing opposition
Bibliography
The patent EP2289531B1 was granted to Fibrogen on Jul 4, 2018 following the initial filing on Dec 6, 2002 under the application number EP10181768A . The current legal status of the patent is Granted And Under Opposition.
Patent Summary
Patent Family New
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Get instant alerts for new documents